Strategies such as miRNA-mediated downregulation of HLA-G expression or inhibition of its interaction with its cognate receptors, akin to current PD-1/PD-L1 immunotherapies, hold promise for stimulating immune responses against the tumor. The gene discussed is HLA-G; the disease is neoplasm.